|
|
Blood, 15 October 2005, Vol. 106, No. 8, pp. 2896-2902.
Prepublished online as a Blood First Edition Paper on July 7, 2005; DOI 10.1182/blood-2005-03-1310.
 Previous Article | Next Article 
Submitted April 8, 2005
Accepted May 27, 2005
A Phase I/II Trial of High-Dose Yttrium 90 ibritumomab tiuxetan in Combination with High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed Non-Hodgkins Lymphoma (NHL)
Auayporn Nademanee*, Stephen Forman, Arturo Molina, Henry Fung, David Smith, Andrew Dagis, Cheuk Kwok, Dave Yamauchi, Anne-Line Anderson, Peter Falk, Amrita Krishnan, Mark Kirschbaum, Neil Kogut, Ryotaro Nakamura, Margaret O'Donnell, Pablo Parker, Leslie Popplewell, Vinod Pullarkat, Roberto Rodriguez, Firoozeh Sahebi, Eileen Smith, David Snyder, Anthony Stein, Ricardo Spielberger, Jasmine Zain, Christine White, and Andrew Raubitschek
Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA
Biogen Idec Inc., Cambridge, MA, USA
Information Services, City of Hope National Medical Center, Duarte, CA, USA
Radioimmuniotherapy, City of Hope National Medical Center, Duarte, CA, USA
Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA, USA
* Corresponding author; email: anademanee{at}coh.org.
We conducted a phase I/II trial of high-dose 90Y ibritumomab tiuxetan in combination with high-dose etoposide (VP16) 40-60 mg/kg (day-4) and cyclophosphamide (CY) 100 mg/kg (day-2) followed by ASCT in 31 patients with CD 20 + NHL. Patients underwent dosimetry (day -21) with 5 mCi 111In-ibritumomab tiuxetan following 250mg/m2 rituximab, followed a week later by 90Y ibritumomab tiuxetan to deliver target dose of 1000 cGy to highest normal organ. Bone marrow biopsy was done on day-7 to estimated radiation dose and stem cells were re-infused when radiation dose was estimated to be <5 cGy. The median 90Y ibritumomab tiuxetan dose was 71.6 mCi (range, 36.6-105). Histology included follicular lymphoma (n=12), diffuse large B-cell (n=14) and mantle cell (n=5). Median number of prior chemo was 2. The treatment was well tolerated. Median time to reach ANC >500/µl and platelet>20,000/µl was 10 days and 12 days, respectively. There were two deaths and 5 relapses. At a median follow-up of 22 months, the 2-year estimated overall survival and relapse-free survival are 92% and 78%, respectively. We conclude that high-dose 90Y ibritumomab tiuxetan can be combined safely with high-dose etoposide and cyclophosphamide without increase in transplant-related toxicity or delayed engraftment.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Will radioimmunotherapy replace TBI?
- Jane N. Winter
Blood 2005 106: 2601-2602.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist,
June 1, 2008;
13(6):
657 - 667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Lazarus, G. L. Phillips, R. H. Herzig, D. D. Hurd, S. N. Wolff, and G. P. Herzig
High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later
J. Clin. Oncol.,
May 10, 2008;
26(14):
2240 - 2243.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Krishnan, A. Nademanee, H. C. Fung, A. A. Raubitschek, A. Molina, D. Yamauchi, R. Rodriguez, R. T. Spielberger, P. Falk, J. M. Palmer, et al.
Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
January 1, 2008;
26(1):
90 - 95.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cremonesi, M. Ferrari, C. M. Grana, A. Vanazzi, M. Stabin, M. Bartolomei, S. Papi, G. Prisco, G. Martinelli, G. Paganelli, et al.
High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment
J. Nucl. Med.,
November 1, 2007;
48(11):
1871 - 1879.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans
Targeted therapy in nuclear medicine current status and future prospects
Ann. Onc.,
November 1, 2007;
18(11):
1782 - 1792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Cooney-Qualter, M. Krailo, A. Angiolillo, R. A. Fawwaz, G. Wiseman, L. Harrison, V. Kohl, P. C. Adamson, J. Ayello, C. vande Ven, et al.
A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non Hodgkin's Lymphoma: A Children's Oncology Group Study
Clin. Cancer Res.,
September 15, 2007;
13(18):
5652s - 5660s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Dearden
Role of antibody therapy in lymphoid malignancies
Br. Med. Bull.,
September 1, 2007;
83(1):
275 - 290.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Devetten and J. Armitage
Hematopoietic cell transplantation: progress and obstacles
Ann. Onc.,
September 1, 2007;
18(9):
1450 - 1456.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press
High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma
J. Clin. Oncol.,
April 10, 2007;
25(11):
1396 - 1402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. F. Khouri
Reduced-Intensity Regimens in Allogeneic Stem-Cell Transplantation for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Hematology,
January 1, 2006;
2006(1):
390 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
